Abstract
4584Background: The therapeutic landscape for metastatic renal cell carcinoma (mRCC) has evolved rapidly with the approval of targeted therapies like tyrosine kinase-, mTOR-, multikinase-, and immu...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have